April 23, 2010 (FinancialWire) — Dara BioSciences, Inc. (NASDAQ: Dara) said that the company has been selected by the Scientific Programme Committee to present results from its Phase 2 study at the Congress on May 29, 2010 in Athens, Greece.

Linda Jett, MSN, clinical director, drug development, Dara BioSciences will present a poster entitled, "Correlation of Numeric Rating Scale, Neuropathic Pain Questionnaire, and Keywords in Study for Treating Neuropathic Pain with KRN5500."

The poster presentation will provide an overview of keywords used by patients in describing their neuropathic pain and the correlation between post-treatment NRS scores and NPQ symptom scores.

KRN5500 is a novel non-opioid analgesic agent, a semi-synthetic derivative of spicamycin.

Neuropathic pain has multiple etiologies, including direct nerve trauma, infectious disease (e.g., herpes zoster), metabolic disease (e.g., diabetes) and drug-induced neuropathies (e.g., chemotherapy).

Chronic neuropathic pain is characterized by an abnormal hypersensitivity to innocuous as well as noxious stimuli, and often persists after initial tissue damage and inflammation appear to have healed. Painful neuropathy is more commonly caused by non-traumatic conditions than by direct nerve trauma.

Clinically, neuropathic pain is difficult to manage and can have a profound impact on quality of life. Although this type of pain sometimes responds well to standard analgesic treatments, very frequently, the response is less than complete, and currently approved therapeutic agents often have intolerable side effects as well. Thus, there is continued need to develop safe and more effective drugs to treat chronic neuropathic pain.

Dara BioSciences, Inc. is a Raleigh, North Carolina-based biopharmaceutical development company that acquires promising therapeutic candidates and develops them through proof of concept in humans for subsequent sale or out-licensing to larger pharmaceutical companies.

Streaming Research for all companies mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate, courtesy of Stock Smart (at http://investrend.stocksmart.com/ss/html/hpcompany.html).

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (at http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

[frlylrf] [biomedphrm] [bsnnssb] [dvcmntnmc] [cnfrncvntprsntn] [prsnttnsntt]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.